Skip to main content
Erschienen in: Journal of Immigrant and Minority Health 6/2010

01.12.2010 | Original Paper

Prevalence of Tuberculin Skin Test Positivity in Clinical Population in New York City

verfasst von: Jiehui Li, Sonal S. Munsiff, Tracy B. Agerton

Erschienen in: Journal of Immigrant and Minority Health | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of latent tuberculosis infection (LTBI) in the various populations of New York City (NYC), a city with a high density of non-US-born persons, is unknown. We examined the prevalence of TST positivity in patients who received a tuberculin skin test (TST) between 1/2002 and 8/2004 at any of 10 NYC health department chest centers. A positive TST was defined as an induration reaction to tuberculin of ≥10 mm. In the study population of 41,022 individuals, prevalence of TST positivity was 24.4% (95%CI = 24.0, 24.8); four times higher among non-US-born persons than US-born (39.5% vs. 8.8%, Prevalence ratio (PR) = 4.5; 95%CI = 4.4, 4.6). Prevalence of TST positivity increased with age in both US and non-US-born persons. Persons from countries with a TB case rate >100/100,000 population had higher prevalence of TST positivity (47% vs. ≤39%), even after controlling for BCG (PR = 1.3, 95%CI = 1.2, 1.4). These findings provide insight into current prevalence of TST positivity in many immigrant populations and will help both clinicians and health departments to target patients for LTBI treatment.
Literatur
1.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb Mortal Wkly Rep. 2000;49(RR-6):1–51. Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb Mortal Wkly Rep. 2000;49(RR-6):1–51.
2.
Zurück zum Zitat Institute of Medicine (US). Committee on the Elimination of Tuberculosis in the United States. In: Geiter L, editor. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press; 2000. Institute of Medicine (US). Committee on the Elimination of Tuberculosis in the United States. In: Geiter L, editor. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
3.
Zurück zum Zitat Centers for Disease Control, Prevention (CDC). Reported Tuberculosis in the United States, 2006. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2007. Centers for Disease Control, Prevention (CDC). Reported Tuberculosis in the United States, 2006. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2007.
4.
Zurück zum Zitat New York City Department of Health and Mental Hygiene: Tuberculosis in New York City, 2005: Annual Summary. New York City Department of Health and Mental Hygiene; 2006. New York City Department of Health and Mental Hygiene: Tuberculosis in New York City, 2005: Annual Summary. New York City Department of Health and Mental Hygiene; 2006.
5.
Zurück zum Zitat Bennett DE, Courval JM, Onorato I, Agerton T, Daugherty Gibson J, Lambert L, et al. Prevalence of tuberculosis infection in the U.S. population. Am J Respir Crit Care Med. 2007;177(3):348–55.CrossRefPubMed Bennett DE, Courval JM, Onorato I, Agerton T, Daugherty Gibson J, Lambert L, et al. Prevalence of tuberculosis infection in the U.S. population. Am J Respir Crit Care Med. 2007;177(3):348–55.CrossRefPubMed
6.
Zurück zum Zitat Joos TJ, Miller WC, Murdoch DM. Tuberculin reactivity in bacilli Calmette-Guerin vaccinated populations: a compilation of international data. Int J Tuberc Lung Dis. 2006;10(8):883–91.PubMed Joos TJ, Miller WC, Murdoch DM. Tuberculin reactivity in bacilli Calmette-Guerin vaccinated populations: a compilation of international data. Int J Tuberc Lung Dis. 2006;10(8):883–91.PubMed
10.
Zurück zum Zitat World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing. WHO Report 2005. Geneva, Switzerland, WHO/HTM/TB/2005.349. World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing. WHO Report 2005. Geneva, Switzerland, WHO/HTM/TB/2005.349.
12.
Zurück zum Zitat Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol. 2004;160:301–5.CrossRefPubMed Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol. 2004;160:301–5.CrossRefPubMed
13.
Zurück zum Zitat Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162:199–205.CrossRefPubMed Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162:199–205.CrossRefPubMed
14.
Zurück zum Zitat Pearce N. Effect measures in prevalence studies. Environ Health Perspect. 2004;112:1047–50.CrossRefPubMed Pearce N. Effect measures in prevalence studies. Environ Health Perspect. 2004;112:1047–50.CrossRefPubMed
15.
Zurück zum Zitat Pai M, Riley LW, Colford JM Jr. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761–76.CrossRefPubMed Pai M, Riley LW, Colford JM Jr. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761–76.CrossRefPubMed
16.
Zurück zum Zitat Mazurek GH, Jereb J, LoBue P, Iademarco MF, Metchock B, Vernon A, et al. Guidelines for using the QuantFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54(RR-15):49–55.PubMed Mazurek GH, Jereb J, LoBue P, Iademarco MF, Metchock B, Vernon A, et al. Guidelines for using the QuantFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54(RR-15):49–55.PubMed
17.
Zurück zum Zitat Pai M, Dheda K, Cunningham J, Scano F, O’Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis. 2007;7(6):428–38.CrossRefPubMed Pai M, Dheda K, Cunningham J, Scano F, O’Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis. 2007;7(6):428–38.CrossRefPubMed
18.
Zurück zum Zitat Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014–18.CrossRefPubMed Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014–18.CrossRefPubMed
19.
Zurück zum Zitat Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tubercullin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med. 1997;127:1051–61.PubMed Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tubercullin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med. 1997;127:1051–61.PubMed
20.
Zurück zum Zitat Schluger NW, Huberman R, Wolinsky N, Dooley R, Rom WN, Holzman RS. Tuberculosis infection and disease among persons seeking social services in New York City. Int J Tuberc Lung Dis. 1997;1:31–7.PubMed Schluger NW, Huberman R, Wolinsky N, Dooley R, Rom WN, Holzman RS. Tuberculosis infection and disease among persons seeking social services in New York City. Int J Tuberc Lung Dis. 1997;1:31–7.PubMed
21.
Zurück zum Zitat Hudson J, Van Zetta S, Brissette B, Driver CR, Macaraig M, Winters A, et al. Tuberculosis transmission in a homeless shelter population–New York, 2000–2003. MMWR. 2005;54:149–52. Hudson J, Van Zetta S, Brissette B, Driver CR, Macaraig M, Winters A, et al. Tuberculosis transmission in a homeless shelter population–New York, 2000–2003. MMWR. 2005;54:149–52.
22.
Zurück zum Zitat Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192–204.PubMed Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192–204.PubMed
Metadaten
Titel
Prevalence of Tuberculin Skin Test Positivity in Clinical Population in New York City
verfasst von
Jiehui Li
Sonal S. Munsiff
Tracy B. Agerton
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Journal of Immigrant and Minority Health / Ausgabe 6/2010
Print ISSN: 1557-1912
Elektronische ISSN: 1557-1920
DOI
https://doi.org/10.1007/s10903-008-9204-9

Weitere Artikel der Ausgabe 6/2010

Journal of Immigrant and Minority Health 6/2010 Zur Ausgabe